Research programme: antibody drug conjugates - Concortis/Eisai Inc
Latest Information Update: 23 Jan 2020
Price :
$50 *
At a glance
- Originator Concortis Biosystems Corp; Morphotek
- Developer Concortis Biotherapeutics; Morphotek
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 25 Jun 2014 Early research in Cancer in USA (Parenteral)